Intersect ENT (XENT) Receiving Somewhat Favorable Media Coverage, Study Shows

$43's average target is 3.99% above currents $41.35 stock price. The medical equipment provider reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.06.

Adage Capital Partners Gp Llc who had been investing in Intersect Ent Inc for a number of months, seems to be bullish on the $1.24B market cap company.

In other news, COO Richard E. Kaufman sold 958 shares of Intersect ENT stock in a transaction on Thursday, February 1st. About 132,664 shares traded.

China's aircraft carrier conducts drill off Taiwan
The Chinese government had earlier notified vessels in the area of plans to conduct the drill, it said. China's defense ministry did not immediately respond to questions.

Chevron (CVX) Given Hold Rating at Royal Bank of Canada
It is positive, as 51 investors sold CVX shares while 686 reduced holdings. 122 funds opened positions while 608 raised stakes. Scotiabank set a $114.00 target price on Chevron and gave the stock a "buy" rating in a research report on Monday, March 27th.

Morgan Stanley (NYSE:MS) Earns Buy Rating from Keefe, Bruyette & Woods
Morgan Stanley's payout ratio is 27.78%. 606.34 million shares or 1.77% less from 617.24 million shares in 2017Q3 were reported. Commerzbank Aktiengesellschaft FI owned about 0.08% of Morgan Stanley worth $60,521,000 at the end of the most recent quarter.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Tuesday, February 27th. XENT outperformed by 113.31% the S&P500. It also reduced its holding in Cenovus Energy Inc (NYSE:CVE) by 2.05M shares in the quarter, leaving it with 50,000 shares, and cut its stake in Motorola Solutions Inc (NYSE:MSI). The institutional investor held 23,277 shares of the specialty foods company at the end of 2017Q4, valued at $3.53 million, up from 20,277 at the end of the previous reported quarter. The firm has a market capitalization of $1,146.00, a P/E ratio of -68.25 and a beta of 0.80. The stock decreased 1.33% or $1.92 during the last trading session, reaching $142.07. About 5.96 million shares traded. Since April 20, 2017 XENT has risen 124.86% and is uptrending. It has underperformed by 13.07% the S&P500. That's 0.00 % from last year's $-0.23 earnings per share. Its down 0.29, from 1.33 in 2017Q3. By selling 97,338 shares Eam Investors Llc made the stock popped up with 18.42%. 29 funds opened positions while 48 raised stakes. The California-based Schwab Charles Mgmt has invested 1.39% in Johnson & Johnson (NYSE:JNJ). Amalgamated Retail Bank reported 0.05% stake. Moreover, State Board Of Administration Of Florida Retirement Systems has 0% invested in J&J Snack Foods Corp. Advisory Serv Net Lc stated it has 0.76% of its portfolio in Johnson & Johnson (NYSE:JNJ). After having $0.21 EPS previously, Brookline Bancorp, Inc.'s analysts see 14.29% EPS growth. Williams Capital Group initiated the shares of NRG in report on Thursday, June 1 with "Buy" rating. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Therefore 40% are positive. Johnson & Johnson had 95 analyst reports since August 7, 2015 according to SRatingsIntel. Finally, Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of Intersect ENT in a report on Wednesday, January 11th. The firm has "Buy" rating by Cowen & Co given on Friday, October 6. The company was maintained on Tuesday, September 29 by Piper Jaffray. The firm has "Overweight" rating by Barclays Capital given on Wednesday, August 10. The rating was maintained by Deutsche Bank on Wednesday, August 2 with "Buy". Intersect ENT earned a news impact score of 0.18 on Accern's scale. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.06. Analysts forecast $-0.23 earnings per share, which is $0.00 or 0.00 % from 2017's $-0.23 earnings per share. Intersect ENT also reported earnings of ($0.23) per share in the same quarter a year ago. (NASDAQ:BRKL) on Monday, February 5. (NASDAQ:XENT) reached all time high today, Apr, 19 and still has $42.80 target or 3.00 % above today's $41.55 share price. The positive are 67%. Canaccord Genuity reaffirmed a "buy" rating and set a $36.00 price target on shares of Intersect ENT in a report on Monday, December 11th. Northland Capital maintained Intersect ENT, Inc. "Buy" rating has 2, "Sell" are 0, while 1 are "Hold". JP Morgan downgraded Intersect ENT, Inc. (NASDAQ:XENT) rating on Wednesday, August 2. Northland Capital initiated Intersect ENT, Inc. On Wednesday, December 6 the rating was maintained by Canaccord Genuity with "Buy". As per Monday, August 21, the company rating was upgraded by Sandler O'Neill.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.